For other inquiries, please contact us here:


For other inquiries, please contact us here:



Neal Curran joins Merz Therapeutics as Global Head of Business Strategy and Portfolio Innovation

Upper Polygon
Lower Polygone

Frankfurt am Main, Germany / Raleigh, United States, 16.11.2023 – Merz Therapeutics announces the appointment of Neal Curran as the Global Head of Business Strategy and Portfolio Innovation. In this strategic role, Neal will be a key driver in shaping the future of the company’s business development and portfolio expansion efforts.



Neal’s primary responsibility will be to formulate the business development and licensing plan, in addition to sourcing and executing transactions for Merz Therapeutics. He will be instrumental in driving critical business development opportunities, including partnerships, licenses, joint ventures, as well as Merger & Acquisition initiatives that align with the overall strategy, business plan, and product portfolio of Merz Therapeutics. Neal will be operating from Raleigh, overseeing his global role and collaborating closely with teams on both continents.

Stefan König, CEO of Merz Therapeutics, expressed his enthusiasm about Neal Curran joining the team, stating, “We are thrilled to welcome Neal to Merz Therapeutics. His extensive experience and strategic vision will be pivotal in advancing our growth and innovation in the field of neurology-focused specialty pharma.”

The appointment of Neal Curran as the Global Head of Business Strategy and Portfolio Innovation reinforces Merz Therapeutics’ commitment to strategic growth and innovation. The company looks forward to this new chapter and the contributions that Neal will make to its continued success.

Neal joins the company after spending the last 18 years at GSK, primarily in Business Development roles. Neal began his business development career at GSK in the transactions team, working to execute deals across all therapeutic areas and stages of development before moving into strategy setting and search/ evaluation roles for specific therapy areas within GSK. Neal’s most recent role at GSK was Vice President, Human Genetics Business Development, where he led a business development team searching for assets with the strongest genetic evidence and delivered on several key clinical and pre-clinical deals across various therapy areas for the company. Prior to GSK, Neal spent 5 years in consulting to start his career.

About Merz Therapeutics
Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.

Please visit

Agnes Tesch
Head of Global Communications & Sustainability
Merz Therapeutics

office: +49 69-1503-2129 I mobile: +49 172 4309370
Merz Therapeutics GmbH
Eckenheimer Landstraße 100
60318 Frankfurt, Germany